GlassScriptPhysician profile
Sandy K Riley
NPI 1558603589
$4,648.05
in general payments reported to CMS, 2019-2025
33 companies · $783 in 2025
The $783 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $709 · 2022: $809 · 2023: $1,153 · 2024: $1,194 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,129.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,218.25 | 2021-2025 | |
| Amgen INC. | $650.27 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $524.53 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $369.56 | 2021-2024 | |
| Novo Nordisk INC | $362.02 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $286.53 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Dexcom, INC. | $216.18 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $116.58 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.47 | 2022-2024 | Xifaxan |
| Shield Therapeutics INC | $67.66 | 2022-2023 | Accrufer |
| Novartis Pharmaceuticals Corporation | $61.77 | 2022-2024 | |
| Insulet Corporation | $57.32 | 2023 | Omnipod |
| Otsuka America Pharmaceutical, INC. | $55.28 | 2023-2025 | Rexulti, Nuedexta |
| Exact Sciences Corporation | $52.35 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $50.96 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $48.22 | 2022-2023 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.59 | 2022-2024 | Jardiance |
| Astellas Pharma US INC | $44.17 | 2022-2024 | Veozah |
| Paratek Pharmaceuticals, INC. | $37.25 | 2022-2023 | Nuzyra |
| Biohaven Pharmaceutical Holding Company LTD. | $35.64 | 2022 | |
| Axsome Therapeutics, INC. | $35.35 | 2025 | Auvelity, Symbravo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.18 | 2024-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $24.63 | 2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $24.43 | 2021 | |
| Abbott Laboratories | $22.17 | 2021 | |
| Lundbeck LLC | $21.52 | 2023 | Rexulti |
| Phathom Pharmaceuticals, INC. | $17.59 | 2024 | Voquezna |
| Biomarin Pharmaceutical INC. | $16.87 | 2024 | Voxzogo 1.2mg |
| E.R. Squibb & Sons, L.L.C. | $16.60 | 2024 | Camzyos |
| Cipher Pharmaceuticals US LLC | $15.16 | 2025 | Natroba, Spinosad |
| Genentech USA, INC. | $12.82 | 2022 | |
| Esperion Therapeutics, INC. | $12.40 | 2021 | |
| Scynexis, INC. | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.